THE DEAL, AT A GLANCE
2/4 reviewedAi3Bio
Ai3Bio
Ai3Bio makes experimental immune treatments that remove disease-causing Th17 cells in autoimmune diseases.
Ai3Bio raised $48M Series A, announced 2026-09-3001What it doesAi3Bio makes experimental immune treatments that remove disease-causing Th17 cells in autoimmune diseases.Source-grounded · automated review · Explore ↗
Checked 2026-10-03 · Review due 2026-10-10
Read supporting source ↗ai3Bio’s proprietary antibody and lipid…
02Who is involvedBacked by founding investors UPMC Enterprises, Ziff Capital Partners, with support from Cockrell Interests, Tanis VenturesFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedAi3Bio raised $48M Series A, announced 2026-09-30From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersThe funding supports studies toward first human trials for its two autoimmune-disease treatment approaches.Source-grounded · automated review · Explore ↗
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Ai3Bio · Financing Record
Explore source-linked visual explanations for Ai3Bio. Unsupported claims are withheld while source review continues.
Record 13302 · Recorded date: 2026-09-30
Explore company records →